Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.66
Bid: 8.80
Ask: 9.78
Change: 0.39 (4.38%)
Spread: 0.98 (11.136%)
Open: 9.00
High: 9.66
Low: 9.00
Prev. Close: 8.90
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

OBD US subsidiary and commercial lead

2 Apr 2019 07:00

RNS Number : 7497U
Oxford BioDynamics PLC
02 April 2019
 

2 April 2019

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Oxford BioDynamics establishes US subsidiary and appoints new commercial lead to drive further US market penetration

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces that it has, in line with its strategy to expand in the US, formed Oxford BioDynamics Inc, a fully-owned subsidiary of Oxford BioDynamics plc and appointed Glen Ferguson as Senior Vice President, USA, to lead the Group's business development activities in the United States.

 

Glen Ferguson joins OBD from HealthTell Inc, where he was Vice President, Corporate Development from 2014. At HealthTell, Glen developed and led strategic growth initiatives driving the personalised medicine offering to pharmaceutical and companion diagnostic businesses. Glen brings significant experience in licensing and contract negotiation, developing strategic alliances, and expertise in the field of companion diagnostics, gained in a life sciences industry career spanning over 25 years. Previously, he held senior positions at ApoCell, where he was Vice President, Molecular Biomarkers, Beckman Coulter, Genaissance Pharmaceuticals, and Bristol Myers Squibb, amongst others.

 

Glen will lead OBD's US-based business development activities, working closely with the Group's executive management team to serve OBD's US partners, customers and collaborators, several of whom Glen has worked with in his previous roles. He will also take up the position of President of Oxford BioDynamics Inc.

 

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

 

"Glen is a strong addition to the OBD leadership team, bringing a wealth of experience in global corporate development and strategic partnerships. Glen's appointment, and the formation of our new US subsidiary, reinforce our commitment to our business development, particularly in the US, the world's largest healthcare market."

 

-ENDS-

 

For further details please contact:

 

Oxford BioDynamics Plc

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

+44 (0)1865 518910

FTI Consulting

Financial Public Relations Adviser

Brett Pollard

Natalie Garland-Collins

+44 (0)20 3727 1000

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAQFLFBKZFXBBV
Date   Source Headline
11th Apr 20242:36 pmRNSHolding(s) in Company
10th Apr 20244:28 pmRNSHolding(s) in Company
9th Apr 20245:35 pmRNSHolding(s) in Company
9th Apr 202412:42 pmRNSHolding(s) in Company
9th Apr 202411:56 amRNSHolding(s) in Company
5th Apr 20248:28 amRNSHolding(s) in Company
3rd Apr 202412:57 pmRNSResults of GM
3rd Apr 20247:00 amRNSOBD opens UK clinical testing facility
27th Mar 20242:18 pmRNSResult of AGM
14th Mar 20247:00 amRNSResults of Fundraising
13th Mar 20244:45 pmRNSPrimaryBid Offer
13th Mar 20244:40 pmRNSProposed Fundraising
22nd Feb 20242:30 pmRNSAnnual Report & Accounts
17th Jan 20247:00 amRNSPreliminary Results and Notice of AGM
21st Dec 20237:20 amRNSNotice of Results
13th Nov 202310:22 amRNSDirector/PDMR Shareholding
8th Nov 20237:00 amRNSOBD strengths commercial leadership
7th Nov 202312:30 pmRNSHolding(s) in Company
6th Nov 20235:04 pmRNSHolding(s) in Company
3rd Nov 20239:29 amRNSDirector/PDMR Shareholding
23rd Oct 202311:09 amRNSPDMR Dealing / Grant of Share Options
20th Oct 20239:45 amRNSDirector/PDMR Shareholding
18th Oct 20237:00 amRNSBupa UK to cover EpiSwitch® CiRT for customers
6th Oct 20235:44 pmRNSDirector/PDMR Shareholding
3rd Oct 20234:37 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSOBD receives reimbursement code for PSE test
26th Sep 20237:00 amRNSOBD launches 94% accurate PSE test in US and UK
7th Sep 202310:18 amRNSHolding(s) in Company
1st Sep 202312:34 pmRNSAmendment: Director/PDMR Shareholding
31st Aug 20234:02 pmRNSHolding(s) in Company
25th Aug 20239:00 amRNSHolding(s) in Company
22nd Aug 20233:58 pmRNSHolding(s) in Company
22nd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20237:00 amRNSHolding(s) in Company
18th Aug 202311:44 amRNSResult of General Meeting
8th Aug 20234:00 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSResults of PrimaryBid Offer
2nd Aug 20237:00 amRNSResult of Placing and Subscription
1st Aug 20234:55 pmRNSPrimaryBid Offer
1st Aug 20234:54 pmRNSProposed Fundraising
30th May 20237:00 amRNSHalf-year Report
16th May 20237:00 amRNSNotice of Interim Results and Investor Webinar
15th May 20237:00 amRNSCiRT expanded validation for ICI immunotherapies
2nd May 20237:00 amRNSUS PACT Award for prognosis test for IOrelated HPD
18th Apr 20237:00 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSBusiness update for PSE and CiRT tests
30th Mar 20231:04 pmRNSResult of AGM
23rd Mar 20233:19 pmRNSHolding(s) in Company
22nd Mar 20232:22 pmRNSHolding(s) in Company
15th Mar 202311:43 amRNSAIM Rule 17 Schedule 2(g) Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.